Pfizer fleshes out oncology strategy, targeting 8 blockbuster cancer drugs by 2030
Following its acquisition of Seattle-based Seagen, Pfizer has systemically laid out its new oncology strategy and aims to have at least eight blockbuster cancer drugs by 2030. The new plan also sees Pfizer focusing on four main cancer types—breast cancer, genitourinary cancer, blood cancer and thoracic cancers—all of which the company already has commercial products in.
Pfizer hopes to double the number of patients treated with its innovative cancer medicines by 2030, from about 2.3 million in 2023.